PANOVSKÁ, Anna, L. SMOLEJ, D. LYSÁK, Yvona BRYCHTOVÁ, M. ŠIMKOVIČ, M. MOTYČKOVÁ, P. VODÁREK, Michaela LINDTNEROVÁ, Martin TRBUŠEK, Jitka MALČÍKOVÁ, Šárka POSPÍŠILOVÁ, Jiří MAYER and Michael DOUBEK. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. European Journal of Haematology. Kopenhagen: Wiley-Blackwell, Munksgaard Int. Publ. Ltd., 2013, vol. 90, No 6, p. 479-485. ISSN 0902-4441. doi:10.1111/ejh.12106.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
Authors PANOVSKÁ, Anna (203 Czech Republic, belonging to the institution), L. SMOLEJ (203 Czech Republic), D. LYSÁK (203 Czech Republic), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), M. ŠIMKOVIČ (203 Czech Republic), M. MOTYČKOVÁ (203 Czech Republic), P. VODÁREK (203 Czech Republic), Michaela LINDTNEROVÁ (203 Czech Republic, belonging to the institution), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Michael DOUBEK (203 Czech Republic, guarantor, belonging to the institution).
Edition European Journal of Haematology, Kopenhagen, Wiley-Blackwell, Munksgaard Int. Publ. Ltd. 2013, 0902-4441.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Denmark
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.414
RIV identification code RIV/00216224:14740/13:00065583
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1111/ejh.12106
UT WoS 000319143100003
Keywords in English chronic lymhocytic leukemia; FRC chemoimmunotherapy; relapse; survival
Tags podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 3. 4. 2014 04:24.
Abstract
Background There is minimal data about the efficacy of subsequent therapy in patients with relapse after FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Methods We retrospectively analyzed the outcomes of 119 patients who relapsed after standard-dose FCR. The patient cohort consisted of patients who relapsed after FCR administered as first-line therapy (Group 1, n=63) and patients relapsing after FCR administered in second/subsequent line; (Group 2, n=56). Results Basic parameters (age, clinical stage, cytogenetics, molecular genetics) did not differ significantly between these subgroups. Likewise, median progression-free survival (PFS) was not considerably different after FCR (18.6 vs. 14.7 months). Subsequent therapy for relapsed disease included FCR retreatment, R-CHOP, alemtuzumab, or rituximab plus high-dose dexamethasone. Overall response rates for the two groups did not significantly differ (59% vs. 44%). Although PFS after subsequent therapy was relatively short, longer PFS was observed in Group 1 (13.3 vs. 5.9 months; P=0.01), in patients with response duration 24 months after previous FCR (13 vs. 6.1 months; 0.01), and in patients who achieved complete remission after FCR (10.8 vs. 7.9 months in partial remission; P=0.01). Newly detected 17p deletions were observed in 5/62 patients, and new p53 mutations in 6/34 FCR-treated patients. Conclusion Our data indicate that the prognosis of patients who relapse after FCR remains poor regardless of the subsequent treatment regimen.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
EE2.3.20.0045, research and development projectName: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny
FR-TI2/254, research and development projectName: *Real-time PCR soupravy pro diagnostiku v onkologii (Acronym: ONKOKITY)
Investor: Ministry of Industry and Trade of the CR
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
NT13493, research and development projectName: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
NT13519, research and development projectName: Časná identifikace CLL pacientů s dosud nevyselektovanými mutacemi v proteinu p53
PrintDisplayed: 1. 7. 2022 04:37